These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 16540937)

  • 1. The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes.
    van de Vijver DA; Wensing AM; Angarano G; Asjö B; Balotta C; Boeri E; Camacho R; Chaix ML; Costagliola D; De Luca A; Derdelinckx I; Grossman Z; Hamouda O; Hatzakis A; Hemmer R; Hoepelman A; Horban A; Korn K; Kücherer C; Leitner T; Loveday C; MacRae E; Maljkovic I; de Mendoza C; Meyer L; Nielsen C; Op de Coul EL; Ormaasen V; Paraskevis D; Perrin L; Puchhammer-Stöckl E; Ruiz L; Salminen M; Schmit JC; Schneider F; Schuurman R; Soriano V; Stanczak G; Stanojevic M; Vandamme AM; Van Laethem K; Violin M; Wilbe K; Yerly S; Zazzi M; Boucher CA
    J Acquir Immune Defic Syndr; 2006 Mar; 41(3):352-60. PubMed ID: 16540937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative analysis of drug resistance among B and the most prevalent non-B HIV type 1 subtypes (C, F, and CRF02_AG) in Italy.
    Santoro MM; Alteri C; Ronga L; Flandre P; Fabeni L; Mercurio F; D'Arrigo R; Gori C; Palamara G; Bertoli A; Forbici F; Salpini R; Boumis E; Tozzi V; Visco-Comandini U; Zaccarelli M; Van Houtte M; Pattery T; Narciso P; Antinori A; Ceccherini-Silberstein F; Perno CF
    AIDS Res Hum Retroviruses; 2012 Oct; 28(10):1285-93. PubMed ID: 22417570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic barrier to the development of resistance to rilpivirine and etravirine between HIV-1 subtypes CRF02_AG and B.
    Fofana DB; Soulie C; Maiga AI; Fourati S; Malet I; Wirden M; Tounkara A; Traore HA; Calvez V; Marcelin AG; Lambert-Niclot S
    J Antimicrob Chemother; 2013 Nov; 68(11):2515-20. PubMed ID: 23833185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV type 1 pol gene diversity and antiretroviral drug resistance mutations in Santos, Brazil.
    de Sa-Filho DJ; Soares Mda S; Candido V; Gagliani LH; Cavaliere E; Diaz RS; Caseiro MM
    AIDS Res Hum Retroviruses; 2008 Mar; 24(3):347-53. PubMed ID: 18327988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to the most recent protease and non-nucleoside reverse transcriptase inhibitors across HIV-1 non-B subtypes.
    Anta L; Blanco JL; Llibre JM; García F; Pérez-Elías MJ; Aguilera A; Pérez-Romero P; Caballero E; Vidal C; Cañizares A; Gutiérrez F; Dalmau D; Iribarren JA; Soriano V; de Mendoza C;
    J Antimicrob Chemother; 2013 Sep; 68(9):1994-2002. PubMed ID: 23629015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prevalence of resistance-associated mutations to protease and reverse transcriptase inhibitors in treatment-naïve (HIV1)-infected individuals in Casablanca, Morocco.
    Bakhouch K; Oulad-Lahcen A; Bensghir R; Blaghen M; Elfilali KM; Ezzikouri S; Abidi O; Hassar M; Wakrim L
    J Infect Dev Ctries; 2009 Jun; 3(5):380-91. PubMed ID: 19759509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphism in HIV-1 non-subtype B protease and reverse transcriptase and its potential impact on drug susceptibility and drug resistance evolution.
    Kantor R; Katzenstein D
    AIDS Rev; 2003; 5(1):25-35. PubMed ID: 12875105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of HIV type 1 subtype on drug resistance mutations in Nigerian patients failing first-line therapy.
    Chaplin B; Eisen G; Idoko J; Onwujekwe D; Idigbe E; Adewole I; Gashau W; Meloni S; Sarr AD; Sankalé JL; Ekong E; Murphy RL; Kanki P
    AIDS Res Hum Retroviruses; 2011 Jan; 27(1):71-80. PubMed ID: 20964479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of drug resistance-related polymorphisms in treatment-naive individuals infected with nonsubtype B HIV type 1 in Cameroon.
    Youngpairoj AS; Alemnji GA; Eno LT; Lyonga EJ; Eloundou MA; Shanmugam V; Mpoudi EN; Folks TM; Kalish ML; Pieniazek D; Fonjungo PN
    AIDS Res Hum Retroviruses; 2012 Jul; 28(7):675-84. PubMed ID: 21923557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV type 1 pol gene diversity and archived nevirapine resistance mutation in pregnant women in Rwanda.
    Servais J; Lambert C; Karita E; Vanhove D; Fischer A; Baurith T; Schmit JC; Schneider F; Hemmer R; Arendt V
    AIDS Res Hum Retroviruses; 2004 Mar; 20(3):279-83. PubMed ID: 15117451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subtype-specific patterns in HIV Type 1 reverse transcriptase and protease in Oyo State, Nigeria: implications for drug resistance and host response.
    Ojesina AI; Sankalé JL; Odaibo G; Langevin S; Meloni ST; Sarr AD; Olaleye D; Kanki PJ
    AIDS Res Hum Retroviruses; 2006 Aug; 22(8):770-9. PubMed ID: 16910833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes.
    Maïga AI; Malet I; Soulie C; Derache A; Koita V; Amellal B; Tchertanov L; Delelis O; Morand-Joubert L; Mouscadet JF; Murphy R; Cissé M; Katlama C; Calvez V; Marcelin AG
    Antivir Ther; 2009; 14(1):123-9. PubMed ID: 19320246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. pol gene diversity of five human immunodeficiency virus type 1 subtypes: evidence for naturally occurring mutations that contribute to drug resistance, limited recombination patterns, and common ancestry for subtypes B and D.
    Cornelissen M; van den Burg R; Zorgdrager F; Lukashov V; Goudsmit J
    J Virol; 1997 Sep; 71(9):6348-58. PubMed ID: 9261352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. V118I substitution in the reverse transcriptase gene of HIV type 1 CRF02_AG strains infecting drug-naive individuals in Cameroon.
    Konings FA; Nyambi PN
    AIDS Res Hum Retroviruses; 2004 Jun; 20(6):673-8. PubMed ID: 15242545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients.
    Vergne L; Peeters M; Mpoudi-Ngole E; Bourgeois A; Liegeois F; Toure-Kane C; Mboup S; Mulanga-Kabeya C; Saman E; Jourdan J; Reynes J; Delaporte E
    J Clin Microbiol; 2000 Nov; 38(11):3919-25. PubMed ID: 11060045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and distribution of HIV type 1 genetic diversity and protease inhibitor resistance-associated mutations in Shanghai, P. R. China.
    Zhong P; Kang L; Pan Q; Konings F; Burda S; Ma L; Xue Y; Zheng X; Jin Z; Nyambi P
    J Acquir Immune Defic Syndr; 2003 Sep; 34(1):91-101. PubMed ID: 14501800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nucleotide and amino acid polymorphisms at drug resistance sites in non-B-subtype variants of human immunodeficiency virus type 1.
    Turner D; Brenner B; Moisi D; Detorio M; Cesaire R; Kurimura T; Mori H; Essex M; Maayan S; Wainberg MA
    Antimicrob Agents Chemother; 2004 Aug; 48(8):2993-8. PubMed ID: 15273111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.
    Nijhuis M; van Maarseveen NM; Lastere S; Schipper P; Coakley E; Glass B; Rovenska M; de Jong D; Chappey C; Goedegebuure IW; Heilek-Snyder G; Dulude D; Cammack N; Brakier-Gingras L; Konvalinka J; Parkin N; Kräusslich HG; Brun-Vezinet F; Boucher CA
    PLoS Med; 2007 Jan; 4(1):e36. PubMed ID: 17227139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of HIV-1 protease mutations A71V/T and T74S on M89I/V-mediated protease inhibitor resistance in subtype G isolates.
    Gonzalez LM; Santos AF; Abecasis AB; Van Laethem K; Soares EA; Deforche K; Tanuri A; Camacho R; Vandamme AM; Soares MA
    J Antimicrob Chemother; 2008 Jun; 61(6):1201-4. PubMed ID: 18356151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. HIV Variant Working Group.
    Pieniazek D; Rayfield M; Hu DJ; Nkengasong J; Wiktor SZ; Downing R; Biryahwaho B; Mastro T; Tanuri A; Soriano V; Lal R; Dondero T
    AIDS; 2000 Jul; 14(11):1489-95. PubMed ID: 10983635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.